CorreGene

Executive Summary

CorreGene is a preclinical-stage Chinese gene therapy company founded in 2018 and headquartered in Beijing. The company focuses on developing curative treatments for rare genetic disorders using advanced gene editing and delivery technologies, targeting monogenic diseases with high unmet medical need. Its platform encompasses both in vivo and ex vivo therapeutic approaches, positioning it to address a range of inherited conditions. As a private company with 1-50 employees, CorreGene is at an early development stage, with no disclosed pipeline details or funding history. The company's core strength lies in its proprietary gene editing and delivery capabilities, which could enable durable one-time treatments. However, the lack of publicly available preclinical data or financial backing introduces significant uncertainty. The company's future depends on advancing its lead programs toward IND-enabling studies and establishing partnerships to support development and manufacturing. Given the competitive landscape in China's gene therapy space, CorreGene's success will hinge on demonstrating differentiation and efficacy in preclinical models.

Upcoming Catalysts (preview)

• Q3 2026Lead Program IND-Enabling Studies Initiation40% success
• Q3 2026Preclinical Data Presentation at Major Conference50% success
• Q3 2026Strategic Partnership or Licensing Deal30% success